Viewing Study NCT02476955



Ignite Creation Date: 2024-05-06 @ 7:07 AM
Last Modification Date: 2024-10-26 @ 11:45 AM
Study NCT ID: NCT02476955
Status: TERMINATED
Last Update Posted: 2020-09-30
First Post: 2015-06-10

Brief Title: Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
Sponsor: ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA
Organization: ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA

Study Overview

Official Title: An Open-label Phase 1b Study of ARQ 092 in Combination With Other Antineoplastic Agents in Subjects With Selected Solid Tumors
Status: TERMINATED
Status Verified Date: 2020-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors
Detailed Description: This is an open-label Phase 1b dose escalation study of oral ARQ 092 administered in combination with carboplatin plus paclitaxel Carboplatin Plus Paclitaxel Arm or in combination with paclitaxel alone Paclitaxel Arm in subjects with advanced inoperable metastatic andor recurrent solid tumors or in combination with anastrozole Anastrozole Arm in subjects with ovarian or endometrial cancer

Enrollment in the Carboplatin plus Paclitaxel Arm and Paclitaxel Alone Arm is now closed Enrollment in the Expansion Cohort for the Anastrozole Arm continues for patients with Endometrial cancer

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
ARQ 092-102 OTHER ArQule Study ID None